|Articles|May 28, 2019

GE Healthcare, World Courier Announce Supply Chain Collaboration

By connecting manufacturing processes and logistics technology, GE Healthcare and World Courier look to accelerate the development of advanced therapies.

GE Healthcare and World Courier, a part of AmerisourceBergen, announced on May 28, 2019 a collaboration to support the commercialization of advanced therapies using GE Healthcare’s FlexFactory manufacturing platform and World Courier’s logistics platform to deliver therapies with time- and temperature-critical conditions globally.

“As GE Healthcare works to advance the development of cell and gene therapies, it is critical that we offer our customers agile solutions that can help them meet global demand. By working with World Courier and leveraging their robust logistics platform and global infrastructure, we are providing a solution that will spur commercialization and access to next-generation therapeutics,” said Catarina Flyborg, general manager, cell and gene therapy, GE Healthcare, in a press statement announcing the collaboration.

“At World Courier, we are committed to moving medicine forward. We’ve developed a proprietary network and global footprint that meets the constantly evolving shipping requirements and complex therapeutics of today. Cell and gene manufacturers deserve a partner that treats patients and their life-changing therapies as well as they would, at every step,” said Sam Herbert, president, World Courier, in the statement. “By collaborating with GE and their FlexFactory platform, we’re taking our commitment one step further and creating an economic and scalable supply chain that helps ensure the efficient and successful delivery of cell and gene therapies to global patients.”

Source: GE Healthcare

 


Related to this article

Stainless steel bioreactor vessels in a manufacturing facility. | Image Credit: © Corona Borealis - stock.adobe.com
Four cell therapy developers have pulled back from ex vivo manufacturing in the past month — ArsenalBio, TScan Therapeutics, and Cellectis all pivoted to in vivo approaches, while Bristol Myers Squibb terminated its manufacturing partnership with automation specialist Cellares after determining its platform couldn't meet requirements for commercial Breyanzi production, triggering layoffs.